Protalix Biotherapeutics Inc (PLX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Protalix Biotherapeutics inc   (NYSEAMER: PLX)


Protalix Biotherapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Protalix Biotherapeutics Inc's ROI in the second quarter of 2026?
Protalix Biotherapeutics inc achieved a return on average invested assets (ROI) of 28.06 % in its second quarter of 2026, this is above PLX's average return on investment of -43.83%.
Protalix Biotherapeutics Inc invested over the 12 months ending in its second quarter of 2026 $68 million

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.

Within the Healthcare sector 33 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 264, from total ROI ranking in the first quarter of 2026 at 272.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 49.27 % 57.57 % 60.99 % 63.52 % 35.23 %
Y / Y Net Income Change TTM 201.91 % 292.32 % - 422.17 % -
Investment (TTM) in Millions 79 75 56 60 54
Return On Investment (TTM) 28.06 % 24.98 % -12 % 10.37 % 13.87 %
PLX's Overall Ranking # 264 # 272 # 2874 # 683 # 418
Seq. Investment Change TTM 10 % 11.53 % 5.8 % 15.01 % 16.12 %
Seq. Net Income Change TTM 23.57 % - - -14.04 % 60.57 %
Net Income (TTM) in Millions 19 15 -7 5 6

PLX Company Profile >> Back to PLX Roi Comparisons >> See Annual PLX Return On Investment



Return On Investment PLX's Ranking
Within: No.
Industry # 8
Sector # 34
Overall # 264

Return On Investment Statistics
High Average Low
110.46 %
-43.83 %
-205.03 %
(Dec 31 2015)   (Sep 30 2017)







Financial Statements
Protalix Biotherapeutics Inc's II. Quarter Investments $ 79 Millions PLX's Balance sheet
Protalix Biotherapeutics Inc's II. Quarter Income $ 4 Millions Quarterly PLX's Income Statement
PLX's Income by Division See PLX's Income by Division


PLX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 49 44 34 19 24
Y / Y Investment Growth 11.7 % 27.67 % 78.66 % -21.11 % -
Net Income in Millions -7 3 8 -15 -28
Y / Y Net Income Growth - -64.73 % - - -
Annual Return On Investment -13.51 % 6.7 % 24.25 % -77.79 % -113.4 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PLX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PLX's Competitors
Subscribers only: Roi for Protalix Biotherapeutics Inc's Suppliers
Subscribers only: Return On Investment for PLX's Customers

Other Ratios
PLX's Roa PLX's Inventory Turnover Ratio PLX's Growth Rates PLX's Dividend Statistics
PLX's Profitability Ratios PLX's Asset Turnover Ratio PLX's Dividend Growth
PLX's Roe PLX's Valuation Ratios PLX's Financial Strength Ratios PLX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %

Date modified: 2026-09-04T10:37:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.